Press Releases

CHEVY CHASE, Md., Oct. 31, 2019 /PRNewswire/ -- Cowork Medical, the Maryland-based medical coworking practice model for physicians, has re-launched its brand

IRVINE, Calif. and COLUMBIA, Md., Oct. 31, 2019 /PRNewswire/ -- Competitive Health and Welldoc announced today a partnership that will offer Competitive Health's clients BlueStar, Welldoc's digital assistant for individuals living with type 2 diabetes. This year, Competitive Health launched the SHOWBenefits platform to its enrolled employ

BEDFORD, N.H., Oct. 31, 2019 /PRNewswire/ -- Back pain affects more people in the U.S. than diabetes, heart disease and cancer combined. It is one of the country's greatest health problems and has played a key role in the opioid crisis that has claimed thousands of unsuspecting victims in the prime of their lives.It is against this backdrop that leading spinal sur

NEWTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Centers for Disease Control has confirmed 1,479 lung injury cases associated with the use of e-cigarettes, or vapes, and 33 deaths. Massachusetts Gov. Charlie Baker ordered the

LOS ANGELES, Oct. 31, 2019 /PRNewswire/ -- Thane and Cynthia Murphy of Assuaged, Inc. are no strangers to physical and mental challenges. This once-bankrupt coupl

MELBOURNE, Australia, Oct. 31, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT) (NASDAQ: BNTC) ("Benitec" or the "Company"), a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced its Appendix 4C for the quarter ending

JERSEY CITY, N.J., Oct. 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data from a post-hoc analysis of the Phase 2b DOVE study investigating the safety and efficacy of oral ibrexafunge

BINYAMINA, Israel, Oct. 31, 2019 /PRNewswire/ -- OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that a review titled, The Pro-Tumorigenic Host Response

TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today t

SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on